Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Heart Failure
100%
Genetic Polymorphism
100%
Pharmacogenomics
100%
Venlafaxine
100%
Cytochrome P450 2D6 (CYP2D6)
42%
CYP2C19
28%
O-desmethylvenlafaxine
28%
Metabolizer
21%
Norepinephrine Reuptake
14%
Cardiomyopathy
14%
Cardiotoxicity
14%
Active Metabolite
14%
Pharmacokinetics
7%
Cardiac Events
7%
High Dose
7%
Genetic Variation
7%
Acute Exposure
7%
Polymorphism
7%
Pain Disorder
7%
Potent Inhibitor
7%
Commercially Available
7%
Major Depressive Disorder
7%
Catecholamines
7%
Clinical Significance
7%
Left Ventricular Dysfunction
7%
Prolonged Exposure
7%
Drug Interactions
7%
Cytochrome P450 3A4 (CYP3A4)
7%
Sustained Hypertension
7%
Treatment for Depression
7%
Anxiety Disorders
7%
Severe Acute
7%
Patient Risk
7%
Serotonin-norepinephrine Reuptake Inhibitors
7%
Catecholamine Levels
7%
Hepatic Enzymes
7%
Metabolic Clearance
7%
Myocardial Injury
7%
Serotonin Reuptake
7%
Dopamine Reuptake
7%
Metabolizer Status
7%
Drug-induced Myopathy
7%
Extensive Metabolizer
7%
Reliable Estimation
7%
Acute Cardiomyopathy
7%
Speculating
7%
Cardiovascular Adverse Events
7%
Symptom Resolution
7%
Cytochrome P450 2C9 (CYP2C9)
7%
Nonischemic Cardiomyopathy
7%
Pharmacogenetic Testing
7%
Treatment of Major Depression
7%
Intermediate Metabolizer
7%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Pharmacogenomics
100%
Venlafaxine
100%
CYP2D6
42%
Myocardial Disease
28%
CYP2C19
28%
Noradrenalin
14%
Catecholamine
14%
Toxic Injury
14%
Cardiotoxicity
14%
Active Metabolite
14%
Adverse Event
7%
Heart Left Ventricle Failure
7%
Long Term Exposure
7%
Serotonin
7%
Major Depression
7%
Drug-Drug Interaction
7%
CYP3A4
7%
CYP2C9
7%
Serotonin-Norepinephrine Reuptake Inhibitor
7%
Liver Enzyme
7%
Anxiety Disorder
7%
Heart Muscle Injury
7%
Psychogenic Pain
7%
Nonischemic Cardiomyopathy
7%
Dopamine
7%
Pharmacokinetics
7%
Diseases
7%
Hypertension
7%